Related Experiment Video
Updated: Dec 25, 2025
07:52
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
20.3K
[Diagnostic imaging of malignant lymphomas].
Theresa Mokry1,2, Paul Flechsig3,4, Sascha Dietrich5
1Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
Der Radiologe
|April 3, 2020
Summary
Imaging is vital for diagnosing and monitoring malignant lymphomas. Fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) with the Deauville score accurately assesses treatment response in lymphoma patients.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Malignant lymphomas constitute about 5% of all cancer diagnoses.
- Medical imaging is essential for lymphoma staging and treatment response assessment.
Purpose of the Study:
- To review the role of imaging in malignant lymphoma patient care.
- To cover initial staging, and treatment monitoring using current classification systems.
Main Methods:
- Literature review of original research and reviews.
- Analysis of clinical guidelines.
Main Results:
- Computed tomography (CT) is the standard diagnostic tool.
- Fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) improves staging and treatment response evaluation for FDG-avid lymphomas.
- The Deauville score on FDG-PET/CT differentiates residual disease and remission.
- Magnetic resonance imaging (MRI) with diffusion-weighted imaging shows future potential but requires standardization.
Conclusions:
- Standardized analysis of morphological and metabolic imaging is crucial for lymphoma treatment decisions.
